Study identifier:NIS-OCN-ARI-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence with Adjuvant Aromatase Inhibitors (AI) medication for Postmenopausal, Early Stage Breast Cancer
Breast Cancer
-
No
-
Female
524
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the 1-year adherence to upfront adjuvant AI for postmenopausal, early stage breast cancer in the two observational arms; Standard Treatment and Standard Treatment plus PSP arm after one year
Location
Location
Beijing, Beijing, China
Location
Chongqing, Chongqing, China
Location
Guangzhou, Guangdong, China
Location
Nanning, Guangxi, China
Location
Harbin, Heilongjiang, China
Location
Wuhan, Hubei, China
Location
Changsha, Hunan, China
Location
Nanjing, Jiangsu, China
Arms | Assigned Interventions |
---|---|
1 Standard Treatment plus PSP | - |
2 Standard Treatment | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.